12:00 AM
May 23, 2016
 |  BC Week In Review  |  Company News  |  Deals

Ability Pharmaceuticals, SciClone deal

Ability granted SciClone exclusive rights to develop and commercialize ABTL0812 in Taiwan, Vietnam and China, including Hong Kong and Macau. Ability will receive...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >